ASX Share rice
Tue 18 May 2021 - 12:37:pm (Sydney)

NEU Share Price

NEUREN PHARMACEUTICALS LIMITEDNEUPharmaceuticals, Biotechnology & Life Sciences

NEU Company Information


Neuren Pharmaceuticals Limited





GIC Industry:


GIC Sub Industry:



697 Burke Road Camberwell VIC Australia 3124


61 3 9092 0480

Chief Exec. Officer:

Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA

CFO & Company Sec.:

Ms. Lauren Frazer C.A.

Chief Science Officer:

Mr. Lawrence Glass

Company Overview:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.

NEU Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


NEU CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


NEU Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Total Revenue:


NEU Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Retained Earnings:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


NEU Share Price History

NEU News

01 Mar, 2021
We can readily understand why investors are attracted to unprofitable companies. For example, although...
30 Nov, 2020
Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups...
03 Jun, 2020
Whilst it may not be a huge deal, we thought it was good to see that the Neuren Pharmaceuticals Limited (ASX:NEU...
19 May, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...